MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock News

Canada - TSX:MDNA - CA58490H1073 - Common Stock

0.92 CAD

-0.02 (-2.13%)

Last: 10/14/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MDNA.CA Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

20 days ago - By: Medicenna Therapeutics Corp.

Medicenna Announces Results of Annual Meeting of Shareholders

20 days ago - By: Medicenna Therapeutics Corp.

Medicenna Announces Results of Annual Meeting of Shareholders

a month ago - By: Medicenna Therapeutics Corp.

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: Medicenna Therapeutics Corp.

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

3 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

3 months ago - By: Medicenna Therapeutics Corp.

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

3 months ago - By: Medicenna Therapeutics Corp.

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

4 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

4 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

4 months ago - By: Stocktwits - Mentions: TNMG GOSS RGBP BIXT ...

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

6 months ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

6 months ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

6 months ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

6 months ago - By: Medicenna Therapeutics Corp.

Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

7 months ago - By: Medicenna Therapeutics Corp.

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

8 months ago - By: Medicenna Therapeutics Corp.

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

8 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

10 months ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

10 months ago - By: Medicenna Therapeutics Corp.

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

a year ago - By: Medicenna Therapeutics Corp.

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

a year ago - By: OTC Markets - Mentions: OTCM

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

a year ago - By: Medicenna Therapeutics Corp.

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Announces Results of Annual Meeting of Shareholders

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Strengthens Board of Directors with Appointment of Karim Lalji

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting

a year ago - By: Medicenna Therapeutics Corp.

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum

a year ago - By: Medicenna Therapeutics Corp.

Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum

a year ago - By: Medicenna Therapeutics Corp.

Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting